José Antonio García Erce: Which Oral Iron Therapy Should We Choose?
José Antonio García Erce, Vocal-elect of the Board of the Spanish Society of Hematology and Hemotherapy, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Journal of Clinical Medicine, adding:
“We are honoured to have published this review with Drs. Santiago García Lopez and Antonio Martínez-Francés in a special issue of Journal of Clinical Medicine (JCM) MDPI: Special Issue Clinical Updates in Transfusion Medicine and Patient Blood Management) open to receive more papers.
Our thanks to Dr Salvador Payán-Pernía for his thorough professional critique which has been instrumental in improving this work”
Title: Iron Deficiency and Oral Treatments: Limitations, Pharmacokinetics, and the Role of Iron Protein Succinylate in Clinical Practice
Authors: José Antonio García-Erce, Santiago García-López, Antonio Martínez-Francés
Other posts featuring José Antonio García Erce on Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke